Sangamo Therapeutics Inc (Sangamo) designs, develops and commercializes engineered zinc finger DNA-binding proteins (ZFPs) for gene regulation and gene modification. The company capitalizes on its patented ZFN technology, strategic collaborations, and focused R&D activities to develop a new class of human therapeutics, and for applications in laboratory research reagents and plant agriculture. History of operating losses products could be an area for concern for the company. The company could benefit from its pipeline products, medical need for hemophilia treatments, and market potential: pain. However, intense competition, intellectual property risk and dependence on third parties could hamper the future business prospects of the company.
Strengths
Weaknesses
Opportunities
Threats
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Access more premium companies when you subscribe to Explorer